They’ve got $5m cash and spending $600k per quarter and increasing. I’d say they are funded for 12 months to be conservative.
It all comes down to R&D delays, and we know that companies in the medical space always have hiccups and delays along the way.
This stock is a buy and forget for 2-3 years. At the current valuation there’s a chance of serious multibagging if positive results.
- Forums
- ASX - By Stock
- NSB
- Ann: Appendix 3B - Escrow Release
Ann: Appendix 3B - Escrow Release, page-3
Add NSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.4¢ |
Change
-0.005(12.8%) |
Mkt cap ! $5.639M |
Open | High | Low | Value | Volume |
3.7¢ | 3.7¢ | 3.4¢ | $21.49K | 608.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 7060 | 3.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.8¢ | 12035 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 26373 | 0.036 |
1 | 50000 | 0.035 |
1 | 230000 | 0.034 |
3 | 160000 | 0.033 |
1 | 200000 | 0.032 |
Price($) | Vol. | No. |
---|---|---|
0.039 | 175000 | 1 |
0.041 | 200000 | 1 |
0.042 | 25000 | 1 |
0.043 | 40000 | 1 |
0.045 | 20000 | 1 |
Last trade - 15.58pm 27/09/2024 (20 minute delay) ? |
NSB (ASX) Chart |
The Watchlist
NRZ
NEURIZER LTD
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online